Promising Esketamine Remains On Track As Potential Depression Blockbuster
Published safety and efficacy Phase II data on J&J's esketamine highlights the antidepressant's potential, fanning interest in 2018 pivotal read-outs.
You may also be interested in...
The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.